GSK (LON:GSK) Insider Julie Brown Acquires 6 Shares

GSK plc (LON:GSK) insider Julie Brown purchased 6 shares of the company’s stock in a transaction that occurred on Tuesday, February 10th. The shares were purchased at an average cost of GBX 2,179 per share, for a total transaction of £130.74.

GSK Stock Down 0.8%

Shares of LON:GSK opened at GBX 2,150 on Thursday. GSK plc has a 1 year low of GBX 1,242.50 and a 1 year high of GBX 2,219. The business has a fifty day moving average price of GBX 1,867.42 and a two-hundred day moving average price of GBX 1,685.32. The company has a market capitalization of £86.75 billion, a PE ratio of 16.17, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73.

GSK (LON:GSK) last released its quarterly earnings results on Wednesday, February 4th. The company reported GBX 172 EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Analysts forecast that GSK plc will post 175.980975 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Citigroup increased their price objective on GSK from GBX 1,900 to GBX 2,250 and gave the company a “buy” rating in a research note on Monday. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a report on Wednesday, January 7th. UBS Group reaffirmed a “neutral” rating and set a GBX 1,940 price objective on shares of GSK in a research note on Friday, January 23rd. Deutsche Bank Aktiengesellschaft raised their target price on GSK from GBX 1,600 to GBX 1,675 and gave the stock a “hold” rating in a research note on Thursday, January 15th. Finally, Shore Capital Group reaffirmed a “buy” rating and set a GBX 2,300 price target on shares of GSK in a research report on Wednesday, February 4th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of GBX 1,917.86.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.